Valuation: iCAD Inc

Market Cap 106M 92.31M 84.83M 79.07M 150M 10.05B 152M 1.02B 396M 4.94B 396M 388M 17.03B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.58M 71.3M 66.46M 126M 8.45B 128M 856M 333M 4.15B 333M 326M 14.31B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer 61 2023-03-09
Director of Finance/CFO 54 2025-07-16
Corporate Secretary - 2025-07-16
Change 5-day change 1-year change 3-year change Capi.($)
+1.97%+2.03%+21.92%+0.83% 195B
+5.87%+5.27%-21.76%+26.78% 151B
+2.17%+0.89%-2.59%-16.42% 140B
+4.83%+2.06%-56.73%-15.69% 67.09B
+2.59%+3.95%+22.89%+3.15% 54.34B
+0.03%+2.19%-25.48%-31.00% 44.64B
+0.31%+1.30%+8.30%+43.25% 37.24B
-2.02%-3.91%+7.67%+9.53% 36.91B
+4.24%+4.66%-18.42%-2.34% 30.27B
Average +2.22%+2.74%-7.13%+2.01% 84B
Weighted average by Cap. +2.78%+3.44%-4.03%+2.02%

Financials

2023 2024
Net sales 17.32M 15.14M 13.91M 12.97M 24.6M 1.65B 24.97M 167M 64.93M 811M 65M 63.61M 2.79B 19.61M 17.14M 15.75M 14.68M 27.85M 1.87B 28.27M 189M 73.52M 918M 73.6M 72.02M 3.16B
Net income -4.85M -4.24M -3.89M -3.63M -6.88M -462M -6.99M -46.75M -18.17M -227M -18.19M -17.8M -782M -5.62M -4.91M -4.51M -4.21M -7.98M -535M -8.1M -54.17M -21.06M -263M -21.08M -20.63M -906M
Net Debt -21.21M -18.54M -17.04M -15.88M -30.12M -2.02B -30.58M -205M -79.52M -993M -79.61M -77.9M -3.42B -16.84M -14.73M -13.53M -12.61M -23.92M -1.6B -24.29M -162M -63.15M -788M -63.23M -61.87M -2.72B
Logo iCAD Inc
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
-